<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738894</url>
  </required_header>
  <id_info>
    <org_study_id>HLX 06-03</org_study_id>
    <nct_id>NCT00738894</nct_id>
  </id_info>
  <brief_title>GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study</brief_title>
  <acronym>HLX 06-03</acronym>
  <official_title>GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients With Patent Foramen Ovale (PFO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine if patent foramen ovale (PFO) closure with the GORE®
      HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder plus antiplatelet medical
      management is safe and effective and reduces the risk of recurrent stroke or
      imaging-confirmed transient ischemic attack (TIA) when compared to antiplatelet medical
      management alone in patients with a PFO and history of cryptogenic stroke or
      imaging-confirmed TIA.

      A co-primary objective is to demonstrate that medical management plus closure with the study
      device reduces the risk of new brain infarct compared to medical management alone
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Actual">April 24, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from recurrent ischemic stroke or imaging-confirmed TIA through at least 24 months post-randomization.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of subjects with new brain infarct or clinical findings of ischemic stroke from screening through 24 months or last follow-up visit, whichever occurs first.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events (AEs) directly related to the device, procedure, and/or antiplatelet medical therapy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Assessment of PFO closure in test (device) arm subjects by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">664</enrollment>
  <condition>Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiplatelet Medical Therapy Alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PFO Closure with GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder Plus Antiplatelet Medical Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder</intervention_name>
    <description>PFO closure with GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder</description>
    <arm_group_label>2</arm_group_label>
    <other_name>GORE® HELEX® Septal Occluder</other_name>
    <other_name>GORE® CARDIOFORM Septal Occluder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antiplatelet Medical Therapy</intervention_name>
    <description>Investigator's choice of one of three regimen options specified in protocol</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Aspirin</other_name>
    <other_name>Dipyridamole</other_name>
    <other_name>Aggrenox</other_name>
    <other_name>Clopidogrel</other_name>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of cryptogenic ischemic stroke or TIA of presumed embolic infarction verified
             by a neurologist within 180 days prior to randomization

          -  Presence of Patent Foramen Ovale (PFO), as determined initially by positive bubble
             study utilizing transesophageal echocardiography (TEE), demonstrating spontaneous
             right-to-left shunting or right-to-left shunting during Valsalva maneuver.

          -  Absence of an identifiable source of thromboembolism in the systemic circulation

          -  No evidence of a hypercoagulable state

          -  Note: Additional Inclusion Criteria may apply

        Exclusion Criteria:

          -  Other co-morbidities including, but not limited to, mural thrombus, dilated
             cardiomyopathy, atrial fibrillation/flutter, cardiac prosthetics (valves), mitral
             valve stenosis, aortic dissection, significant atherosclerosis, vasculitis,
             pre-existing neurologic disorders, multiple sclerosis, arteriovenous malformations,
             prior intracranial hemorrhage, severe central nervous system (CNS) disease, severe
             disability related to prior stroke, and autoimmune disorders that would increase the
             risk of mortality or morbidity above what is typical for the treatment

          -  Previous Myocardial Infarction

          -  Active infection that cannot be treated successfully prior to randomization

          -  Sensitivity or contraindication to all proposed medical treatments

          -  Pregnancy or intent on becoming pregnant through 24-months after randomization

          -  Indications outside the parameters accepted for placement of the GORE® HELEX® Septal
             Occluder / GORE® Septal Occluder, including extensive congenital cardiac anomalies and
             defect diameter estimated to be &gt; 18mm

          -  Atrial septal anatomy that is expected to necessitate placement of more than one GORE®
             HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder

          -  Need for concomitant procedure(s) that may confound detection of adverse events
             related to device placement

          -  Note: Additional Exclusion Criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott E. Kasner, MD, FAHA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John F. Rhodes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Søndergaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Thomassen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital - Bergen, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cryptogenic</keyword>
  <keyword>stroke</keyword>
  <keyword>transient ischemic attack</keyword>
  <keyword>TIA</keyword>
  <keyword>PFO</keyword>
  <keyword>Patent foramen ovale</keyword>
  <keyword>HELEX</keyword>
  <keyword>Septal Occluder</keyword>
  <keyword>PFO Occluder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 16, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

